Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 12/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.60 |
| ▸ | CLK3 | P49761 | 11/20 | 0.60 |
| ▸ | WNT1 | P04628 | 7/20 | 0.58 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20966115 | 0.92 | CLK2 (0.58) | CLK2DYRK1ACLK3WNT1CDK8 | |
| SCHEMBL20966190 | 0.92 | WNT1 (0.59) | CLK2DYRK1ACLK3WNT1CDK8 | |
| SCHEMBL20965650 | 0.90 | CLK2 (0.58) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL20965646 | 0.90 | WNT1 (0.55) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL18453228 | 0.89 | CLK3 (0.55) | CLK2DYRK1ACLK3WNT1CDK8 | |
| SCHEMBL18441947 | 0.89 | DYRK1A (0.78) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL18448425 | 0.88 | DYRK1A (0.76) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL18479365 | 0.88 | WNT1 (0.61) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL18447860 | 0.88 | WNT1 (0.59) | CLK2DYRK1ACLK3WNT1CDK8 | |
| SCHEMBL20965753 | 0.87 | WNT1 (0.57) | CLK2DYRK1ACLK3WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | claimed |
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | WNT1, WNT3A, WNT3 | CLK2 2043/4885DYRK1A 849/4885CLK3 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.